North Charleston, South Carolina - October 17, 2005 - Argolyn Bioscience Inc. announced today that W. Thomas Amick has been elected to its Board of Directors. Mr. Amick has deep operational experience in the pharmaceutical industry including both large multi-national corporations and venture-backed biotechnology companies.

In a 30-year career with Johnson & Johnson (J&J) he served as President of Ortho Biotech Europe, President of Janssen-Ortho, and Vice President of the Oncology Franchise for Ortho Biotech. Most recently, he was Vice President for Business Development of Johnson & Johnson Development Corporation, the venture capital division of J&J. He currently serves as a Venture Partner with A. M. Pappas Ventures; a member of the Advisory Board for Quaker BioVentures; Executive Chairman of Stemco Biomedical; and on the Boards of Directors of BioRexis Pharmaceutical Corporation, Biolex Corporation, Transport Pharmaceuticals, and Discovery Laboratories, Inc.

Mr. Amick earned his BS in Business Administration at Elon University and has taken graduate or executive courses at the University of Virginia, the Kellogg School at Northwestern, and the Harvard Business School.

"Tom is a tremendous addition to the Argolyn team," said Argolyn Bioscience CEO Pearce Gilbert. "Besides bringing his own executive-level and industry-specific experience to the Argolyn Boardroom, Tom also brings the network of industry contacts that result from a long and successful career. We look forward to applying his broad expertise to the many exciting opportunities lying ahead of Argolyn Bioscience."

Argolyn Bioscience Inc.

Argolyn Bioscience Inc. is a peptide product development company headquartered in North Charleston, South Carolina. Argolyn is the exclusive worldwide licensee for a portfolio of patents and patent applications aimed at improving the pharmacology of peptide drug candidates. The company has one product in preclinical development and several other discovery stage product programs.

Argolyn Bioscience continues to seek other opportunities to disseminate the technology either through collaboration or out-licensing. For more information, contact the company or visit the website at www.argolyn.com.

For More Information, Contact:
Pearce Gilbert
Argolyn Bioscience Inc.
Tel: (843) 266-0851
Fax: (843) 266-0894
info@argolyn.com